Board of Directors
Our Board of Directors is composed of industry veterans and clinical experts with expertise to support the company’s goals and vision.
Chairman of the Board
John L. Tullis
Mr. Wahlstrom has more than 35 years of experience in the healthcare industry, having served as CEO and CFO of large international companies in the renal field. Mats currently serves as Executive Chairman of KMG Capital Partners, LLC, Chairman of Caduceus Medical Holdings, Inc., and Chairman of Triomed AB, a medical device company. He also serves as the Lead Director and Chairman of the Audit/Finance Committee of Coherus Biosciences, Inc., a public biotech company. In addition, he serves on the boards of Alteco Medical AB, a public medical device company, and Circuit Clinical Solutions, Inc., a clinical research company.
Mats has also served as a director of Healthgrades, Inc., Zynex, Inc., and Getinge AB, all public companies in the healthcare industry. From January 2004 through December 2009, Mats served as Co-CEO of Fresenius Medical Care North America, and from November 2002 through December 2009 as President and CEO of Fresenius Medical Services, the largest dialysis provider in the U.S. Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including 10 years as CEO of Gambro North America and Gambro Healthcare, Inc., as well as CFO and Executive Vice President of the Gambro Group.
Mr. Hicks currently serves as CEO and President of KMG Capital Partners LLC, a boutique healthcare venture capital company based in Denver, Colorado. As a successful, innovative healthcare executive, Mr. Hicks leverages his extensive healthcare and leadership expertise to provide strategic guidance and drive success within portfolio companies Prior to joining KMG Capital Partners, Mr. Hicks served as Chairman (1998 – 2010) and Chief Executive Officer (1998 – 2012) of Healthgrades since the company’s inception. He led Healthgrades through eleven years of consistent growth as a publicly traded company, and then facilitated the sale of the business to Vestar Capital Partners in 2010. Under his leadership, Healthgrades transformed into the premier destination for consumers seeking information on doctors and hospitals. Mr. Hicks built Healthgrades from a predecessor company, Specialty Care Network, where he served as President and Chief Executive Officer from 1995 to 1999. From 1985 to 1995 he served as Senior Vice President of LBA Healthcare Mr. Hicks currently serves as Executive Chairman of Circuit Clinical, Co-Chairman of Breakout Investment Partners, LLC, and serves on the boards of KMG Capital Partners LLC, Caduceus Medical Holdings, Inc. and TriSalus Life Sciences.
Yongxin Han, PhD
Dr. Yongxin Han has more than 20 years of research and management experience in the pharmaceutical industry. Dr. Han was a Senior Group Leader at Array Biopharma, the cofounder and General Manager of Chemizon and Centaurus BioPharma, and has delivered more than 14 investigational new drug applications. He has been the “Beijing Overseas Talent Plan” winner and was awarded “Beijing Distinguished Experts” and “Beijing One Hundred Leading Talents of Science and Technology.”
Dr. Han is currently a Partner with Lapam Capital LLC, a healthcare Venture Capital firm, and Board Director of BroadenBio Co. Ltd. and VivaVision Co. Ltd. He received his Bachelor of Science from Peking University, Master of Science from the Chinese Academy of Science, and PhD from the University of Minnesota.
With more than 25 years of experience in the medical industry, Gene McGrevin has held senior management positions in global companies including Johnson & Johnson and Kimberly-Clark Corporation. Mr. McGrevin also was instrumental in the expansion and sale of several medical startups. They include PetNet Pharmaceuticals (sold to Siemens), Microtek Medical Holdings (sold to EcoLabs), and Medivance (sold to C.R. Bard). In addition, Mr. McGrevin serves on the Boards of the Yerkes Primate Center, Real Time Medical Data and HydroDynamics.
Mr. McGrevin holds an MBA from the University of Pennsylvania’s Wharton School. He earned a BA in economics at the University of Pittsburgh.
Ms. Parks joins the TriSalus board with more than 30 years of expertise across the biotech, pharmaceutical, and advertising industries. She’s held executive roles at Kite Pharma Inc, Pharmacyclics, Amgen, and Genentech, most recently serving as senior vice president, marketing and account management at Kite Pharma Inc. Ms. Parks is credited with successfully leading the launch of the first-ever CAR-T therapy, YESCARTA.
She holds a Master of Business Administration degree from Georgia State University and received her Bachelor of Arts degree from Kansas State University. Diane currently serves on several other boards including Calliditas Therapeutics, Kura Oncology and Soligenix, all early stage biotechnology companies.
Dr. Singhal has served as Adicet Bio’s President and Chief Executive Officer and a member of the Board of Directors since May 2019. He joined Adicet from Canaan Partners where he served as Executive in Residence and OncoResponse Inc., where he served as Chief Scientific Officer. He is the former Vice President of Early Oncology Development of AbbVie and Head of their Abbvie-Redwood City, California site. During his tenure at AbbVie, he oversaw the global regulatory approval of Empliciti in multiple myeloma. As a member of the R&D leadership team, he helped to guide an impressive portfolio and key translational science capabilities in oncology and other diseases. Dr. Singhal has held senior roles in the U.S., Japanese and German biopharma/biotechnology industry leading to the approvals of Prosorba in auto-immune disease and talaporfin sodium in non-small cell lung cancer. Prior to his industry tenure, he was Assistant Research Professor at Mount Sinai School of Medicine and concurrent with the industry role, Adjunct Associate Professor at University of Washington.
Dr. Singhal holds a PhD in Biochemistry from Rutgers University and an MBA from the University of Washington. He serves on the Board of Directors of TriSalus Inc.
Mrs. Song has more than 25 years of experience in the healthcare sector. Simone is the Founder and Senior Partner of ORI Capital and the former Head of Goldman Sachs Healthcare Investment Banking for Greater China.
Prior to joining Goldman Sachs, Simone was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers, and an executive board advisor to AXA Asia Pacific Holdings.
Simone holds a BA in Economics from Fudan University in China and an MA in Economics from Claremont Graduate School in the United States.
John L. Tullis
Mr. Tullis is President and a Partner at Tullis Health Investors, where he is focused especially on healthcare technology and services, medical devices, and international markets. He has more than 19 years of investing and international business experience. Mr. Tullis currently serves as Chairman of CareSync, Inc. and was also an Executive Committee Member of the Board of Directors of the Beacon Council, Miami-Dade’s Economic Development Organization, for three years.
Mr. Tullis holds a Bachelor’s degree in Liberal Arts from DePauw University. He received a Graduate Certificate from the University of Virginia’s McIntire Business Institute, and a Master’s degree in Business Administration from the University of Miami. At ages 14-15, he studied at a Taiwanese boarding school, where he was the school’s only non-Chinese student.
Ms. Szela has nearly 30 years of experience in both the commercial and clinical arenas. Her accomplishments in building billion-dollar businesses, turning around faltering businesses, igniting growth in stagnant businesses, and devising innovative, differentiated strategies for undistinguished products make for a remarkable record.
Previously, Ms. Szela served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company’s revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus).
Ms. Szela held ascending management positions at Abbott Laboratories including President of the company’s $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Vice President for global strategic marketing and services. Ms. Szela currently serves as a member of the Board of Directors for Coherus Biosciences.
She earned an MBA and a BS in nursing, both from the University of Illinois.
Alan C. Mendelson
Mr. Mendelson was appointed as a director of TriSalus in July 2021 after retiring as a senior partner in Latham & Watkins LLP, a major global law firm. During 47+ years of practice, he represented emerging and public growth companies, primarily in the life sciences industry, and served as Global Co-Chair of the firm’s Life Sciences Industry Group. As its incorporator in 1980, Mendelson played a leading role in Amgen’s first decade, and served as its secretary and acting general counsel for 1990-1991.
Mr. Mendelson serves on a variety of Boards at the University of California, Berkeley, including the Board of Trustees of the UC Berkeley Foundation, as well as the Board of Trustees of the Buck Institute for Research on Aging, and the Board of Directors of the National Kidney Foundation. He also serves on the Board of Directors of Coherus BioSciences, Inc., a public biotechnology company, and several private life science companies.
Recipient of a Life Sciences Leadership Award at the BayBio Pantheon, he is one of only four individuals to have a star in Legal 500’s Hall of Fame for legal professionals serving the life sciences sector.
Mr. Mendelson received his B.A. degree from UC, Berkeley in 1969 and his J.D. degree in 1973 from Harvard.
Sean Murphy has 40+ years’ experience in healthcare operations and business development, encompassing pharmaceuticals, medical devices, and diagnostics. He was appointed a director of TriSalus in September 2021, after serving as Executive Vice President of Malin Life Sciences Holding. A publicly traded investment company, Malin invested for a portfolio of companies that included pharmaceuticals, medical devices, and healthcare services. Additionally, Mr. Murphy has been a Senior Advisor at Evercore Partners, a leading investment-banking advisory firm, and Head of Corporate M&A and Business Development at Abbott Laboratories, where, over 30 years with the company, he played a leading role in strategic and operational investments. Currently, he serves on the board of directors of several life science companies, including Radius Health, Immucor Diagnostics, Xenex, and Prenosis.
A CPA, Mr. Murphy earned an MS in Finance from the University of Illinois and a BBA from Western Illinois University.